A mixture of N-Quinlinioxxyphenil-N-Fenilcyclopadic arboxamida derivatives and an Erbb inhibitor was selected from Lapatinib, Ertinib, GEFITINIB, Trastuzumab, Cetuximab for cancer treatment.

摘要

Use of compounds derived from ciclopropanodicarboxamida replaced and ErbB inhibitor for the treatment of cancers.